Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies
A. Shamseddine(Stony Brook University), Adam M. Schmitt(Memorial Sloan Kettering Cancer Center), Jun Li(Second Affiliated Hospital of Zhejiang University), Nicholas D. Socci, Alessandra Piersigilli(University of Bern), Zachary Moore(Memorial Sloan Kettering Cancer Center), Anthony F. Yu(Memorial Sloan Kettering Cancer Center), Mutayyaba Adnan(Memorial Sloan Kettering Cancer Center), Suchit H. Patel(Memorial Sloan Kettering Cancer Center), Lakshmi V. Ramanathan(Memorial Sloan Kettering Cancer Center), Samuel F. Bakhoum(Memorial Sloan Kettering Cancer Center), Richard M. Steingart(Memorial Sloan Kettering Cancer Center), Chau T. Dang(Memorial Sloan Kettering Cancer Center), Jennifer E. Liu(Memorial Sloan Kettering Cancer Center), Kevin C. Oeffinger(Duke University), Melody Di Bona(Memorial Sloan Kettering Cancer Center), Angel Chan(Memorial Sloan Kettering Cancer Center), Valery Chávez(Memorial Sloan Kettering Cancer Center)
Cited by 26
Related Papers
Chronic Health Conditions in Adult Survivors of Childhood Cancer
|New England Journal of Medicine|2006|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725
Germline mutations in BAP1 predispose to melanocytic tumors
|Nature Genetics|2011|724